A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
Public ClinicalTrials.gov record NCT00699283. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An International, Double-blind, Randomized, Multi-center, Parallel Group, Historical-control Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures With or Without Secondary Generalization.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Antiepileptic Drugs (AEDs) are the main treatment for epilepsy; however, only a limited number of AEDs are approved for use as monotherapy. The objective of this study is to evaluate the efficacy of BRV in the conversion of partial onset seizure patients from combination treatment to monotherapy.
Study identification
- NCT ID
- NCT00699283
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 62 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 16 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2008 (Type not available)
- Primary completion
- Mar 2010 (Actual)
- Completion
- Mar 2010 (Actual)
- Last update posted
- Jul 11, 2018
2008 – 2010
United States locations
- U.S. sites
- 43
- U.S. states
- 27
- U.S. cities
- 43
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Garden Grove | California | — | — |
| Not listed | Loma Linda | California | — | — |
| Not listed | Newport Beach | California | — | — |
| Not listed | Riverside | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | Stanford | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Fort Collins | Colorado | — | — |
| Not listed | Danbury | Connecticut | — | — |
| Not listed | New Haven | Connecticut | — | — |
| Not listed | Waterbury | Connecticut | — | — |
| Not listed | Gainesville | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Honolulu | Hawaii | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Danville | Indiana | — | — |
| Not listed | Elkhart | Indiana | — | — |
| Not listed | Waldorf | Maryland | — | — |
| Not listed | Grand Rapids | Michigan | — | — |
| Not listed | Columbia | Missouri | — | — |
| Not listed | Lebanon | New Hampshire | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Flushing | New York | — | — |
| Not listed | Schenectady | New York | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Oberlin | Ohio | — | — |
| Not listed | Westerville | Ohio | — | — |
| Not listed | Tulsa | Oklahoma | — | — |
| Not listed | Bethlehem | Pennsylvania | — | — |
| Not listed | Jenkintown | Pennsylvania | — | — |
| Not listed | Providence | Rhode Island | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Bedford | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Layton | Utah | — | — |
| Not listed | Ogden | Utah | — | — |
| Not listed | Burlington | Vermont | — | — |
| Not listed | Bluefield | Virginia | — | — |
| Not listed | Seattle | Washington | — | — |
| Not listed | Morgantown | West Virginia | — | — |
| Not listed | Marshfield | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00699283, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 11, 2018 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00699283 live on ClinicalTrials.gov.